Take the CME test and receive
1 ESMO - MORA point
- To provide an update on setting of patients with EGFR-mutated non-small cell lung cancer (NSCLC) and implications for targeted treatments
- To provide a summary of data from clinical studies with EGFR tyrosine kinase inhibitors (TKIs) in patients with NSCLC
- To provide an update on mechanisms of resistance to EGFR TKIs and how to overcome it
This E-Learning module is an update of a previous module focusing on epidermal growth factor receptor (EGFR) inhibition and implications for the treatment of patients with non-small cell lung cancer (NSCLC). The authors elaborate the role of EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutated NSCLC and provide a timeline of development of different EGFR TKIs illustrating the results from relevant clinical trials. They put the achievements from clinical trials, in terms of improved outcomes, into a clinically relevant context.
The module covers a selection of first-line therapy for patients with EGFR mutation positive NSCLC, provides insights on first-line EGFR TKIs that are currently standard of care, explores whether there is a role for EGFR TKIs in the adjuvant and neoadjuvant settings, elaborates a problem of acquired resistance to osimertinib, how to overcome osimertinib resistance in EGFR mutation positive advanced NSCLC, when given in first-line treatment and after progression to osimertinib, and provides a snapshot on future research directions.
The authors underline that, in patients with NSCLC and activating EGFR mutations, EGFR TKIs therapy statistically significantly delays disease progression and should be considered as front-line treatment. Osimertinib is now considered as the preferred option in first-line treatment, especially in presence of EGFR exon 20 T790M mutation.
The authors present data from a range of clinical trials with novel agents, developed since the previous module, they present the following: results with aumolertinib in first-line treatment of patients with EGFR exon 19 del or L858R mutations; the results from a clinical trial with amivantamab plus lazertinib in patients who progressed on osimertinib; the results from a clinical trial in pre-treated patients who received patritumab deruxtecan; the results from a clinical trial in case of exon 20 mutation and treatment with DZD9008, as well as the results from the clinical trials in adjuvant and locally advanced settings.
Dr Morgillo and Dr Fasano have no interests to declare